Eli Lilly and Co to Provide Comprehensive Update on Progress of SARS-CoV-2 Neutralizing Antibody Programs - Conference Call Transcript
Ladies and gentlemen, thank you for standing by. Welcome to the SARS-CoV-2 Neutralizing Antibody Update Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
Now I'd like to turn the conference over to the host, Vice President of Investor Relations, Kevin Hern. Please go ahead.
Good afternoon. Thank you for joining us for Eli Lilly and Company's SARS-CoV-2 Neutralizing Antibody Update. I'm Kevin Hern, Vice President of Investor Relations. Joining me on today's call are Dave Ricks, Lilly's Chairman and CEO; Dr. Dan Skovronsky, Chief Scientific Officer; and Josh Smiley, Chief Financial Officer.
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors as noted on Slide 3. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
